Cigna Drug and Biologic Coverage Policy

Transcription

1 Cigna Drug and Biologic Coverage Policy Subject Interleukin (IL)-5 Antagonists: Mepolizumab and Reslizumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 5 Effective Date.10/15/2017 Next Review Date..10/15/2018 Coverage Policy Number Related Coverage Resources Omalizumab INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna companies. Coverage Policies are intended to provide guidance in interpreting certain standard Cigna benefit plans. Please note, the terms of a customer s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations. Proprietary information of Cigna. Copyright 2017 Cigna Coverage Policy Interleukin (IL)-5 Antagonists include the following: Mepolizumab (Nucala ) Reslizumab (Cinqair ) Cigna covers mepolizumab (Nucala ) as medically necessary for the treatment of asthma when ALL of the following criteria are met: Individual is 12 years of age or older Eosinophilic phenotype defined as EITHER of the following: o Blood eosinophils greater than or equal to 150 cells/mcl within the previous 6 weeks o History of blood eosinophils greater than or equal to 300 cells/mcl Diagnosis of severe asthma (*refer to definition) Continued use of an inhaled corticosteroid AND another controller therapy (for example, long-acting beta-agonist, leukotriene receptor) Will not be used in combination with another monoclonal antibody (for example, reslizumab [Cinqair ], omalizumab [Xolair ]) Cigna covers reslizumab (Cinqair ) as medically necessary for the treatment of asthma when ALL of the following criteria are met: Individual is an adult (18 years of age and older) Eosinophilic phenotype defined as blood eosinophil level of at least 400 cells/mcl Diagnosis of severe asthma (*refer to definition) Continued use of an inhaled corticosteroid AND another controller therapy (for example, long-acting beta-agonist, leukotriene receptor) Page 1 of 7

2 Will not be used in combination with another monoclonal antibody (for example, mepolizumab [Nucala ], omalizumab [Xolair ]) *Severe asthma is defined as EITHER of the following: Inadequate control as defined by ONE of the following on high doses of inhaled corticosteroids with an additional controller (long-acting beta-agonist or leukotriene receptor antagonist/theophylline) o Poor symptom control: Asthma Control Questionnaire (ACT) consistently greater than 1.5 or o Asthma Control Test less than 20 History of exacerbations meeting ONE of the following: Two (2) or more exacerbations requiring at least 3 days of systemic corticosteroids in the previous 12 months One (1) or more severe exacerbation (hospitalization, ICU stay or mechanical ventilation) in the previous 12 months o Demonstrated airflow limitation: after appropriate bronchodilator withhold FEV1 less than 80% predicted (in the face of reduced FEV1/FVC defined as less than the lower limit of normal) Dependence on (for at least 50% of the previous 12 months) or inadequate control with daily oral corticosteroids for maintenance Initial Authorization for mepolizumab (Nucala ) or reslizumab (Cinqair ) is 12 months. Cigna covers continued authorizations of mepolizumab (Nucala ) or reslizumab (Cinqair ) when BOTH of the following criteria are met: History of beneficial clinical response Clinical condition meets initial use criteria Cigna does not cover the use of mepolizumab (Nucala ) or reslizumab (Cinqair) for any other indication including the following because it is considered experimental, investigational or unproven (this list may not be all-inclusive): Relief of acute bronchospasm or status asthmaticus Treatment of other eosinophilic conditions (e.g., for example, eosinophilic esophagitis, hypereosinophilic syndrome, eosinophilic granulomatosis with polyangitis) Nasal polyposis When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to mepolizumab (Nucala ) or reslizumab (Cinqair ). Note: Receipt of sample product does not satisfy any criteria requirements for coverage FDA Approved Indications Product Cinqair (reslizumab) FDA Approved Indications Cinqair is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype [see Clinical Studies (14)]. Limitation of Use: Nucala (mepolizumab) Cinqair is not indicated for treatment of other eosinophilic conditions. Cinqair is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions (5.2)]. Nucala is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. [See Clinical Studies (14).] Limitations of Use Page 2 of 7

3 Nucala is not indicated for treatment of other eosinophilic conditions. Nucala is not indicated for the relief of acute bronchospasm or status asthmaticus. FDA Recommended Dosing Product Cinqair (reslizumab) Nucala (mepolizumab) FDA Recommended Dosing Cinqair is for intravenous infusion only. Do not administer as an intravenous push or bolus. The recommended dosage regimen is 3 mg/kg once every 4 weeks administered by intravenous infusion over minutes [see Dosage and Administration (2.2)]. Discontinue the infusion immediately if the patient experiences a severe systemic reaction, including anaphylaxis [see Contraindications (4), Warnings and Precautions (5.1)]. Recommended Dosage Nucala is for subcutaneous use only. The recommended dose of Nucala is 100 mg administered once every 4 weeks by subcutaneous injection into the upper arm, thigh, or abdomen. Preparation and Administration Nucala should be reconstituted and administered by a healthcare professional. In line with clinical practice, monitoring of patients after administration of biologic agents is recommended [see Warnings and Precautions (5.1)]. Drug Availability Product Cinqair (reslizumab) Nucala (mepolizumab) Drug Availability 100 mg/10 ml (10 mg/ml) solution in single-use vials 100 mg of lyophilized powder in a single-dose vial for reconstitution General Background Pharmacology Mepolizumab and reslizumab are interleukin-5 antagonists. IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation. IL-5 antagonists, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils; however, the mechanism of action in asthma has not been definitively established. (GlaxoSmithKline, 2015; Teva Respiratory, 2016) Guidelines Global Initiative for Asthma (GINA) The GINA s report for asthma management and prevention provide recommendations to consider categorical phenotyping for individuals with severe asthma who are uncontrolled on Step 4 treatment (i.e., using medium- to high-dose inhaled corticosteroid (ICS) plus a long-acting beta-agonist (LABA) or other controller medication). Mepolizumab and reslizumab are listed as a treatment option for individuals with an eosinophilic phenotype. (GINA, 2017) European Respiratory Society/American Thoracic Society (ERS/ATS) Page 3 of 7

4 The ERS/ATS defines severe asthma as those individuals who require treatment with GINA step 4 or 5 medications (high-dose ICS and LABA or leukotriene receptor antagonist or theophylline) for the previous year or systemic corticosteroids for at least 50% of the previous year to prevent the condition from becoming uncontrolled or which remains uncontrolled despite the therapy. (Chung, 2014) Uncontrolled asthma is defined as having at least one of the following: poor symptom control (using standardized measures); frequent severe exacerbations (requiring 2 or more bursts (greater than 3 days) or corticosteroids in the previous year); serious exacerbations (at least one hospitalization, intensive care unit stay or mechanical ventilation in the previous year); or airflow limitation. (Chung, 2014) Controlled asthma that worsens when tapering high doses of inhaled corticosteroids, systemic corticosteroids, or other biologic therapies also meets the definition of severe asthma. (Chung, 2014) Clinical Efficacy There are no trials comparing mepolizumab to reslizumab. Mepolizumab was evaluated in 3 placebo-controlled, randomized trials and reslizumab in 4 placebo-controlled, randomized trials. Mepolizumab (Nucala) The DREAM trial included 621 patients aged 12 to 74 years with severe refractory asthma per American Thoracic Society (ATS) criteria for at least 12 months and taking high-dose inhaled corticosteroids and an additional controller medication. Patients were included if they had at least 2 exacerbations requiring oral or systemic corticosteroids in the previous 12 months. Eosinophilic airway inflammation was defined as either having elevated peripheral blood eosinophils at least 300/mcL, sputum eosinophils at least 3%, exhaled nitric oxide at least 50 parts per billion, or having deterioration of asthma control following at 25% reduction of maintenance inhaled or oral steroids. Patients were randomized to either 75 mg, 250 mg, or 750 mg of intravenous mepolizumab or placebo for a 52-week treatment period. Mepolizumab demonstrated a significant reduction in the number of clinically significant asthma exacerbations per year. (Pavord, 2012) The MENSA trial evaluated 32 weeks of treatment with mepolizumab 75 mg intravenous, 100 mg subcutaneously or placebo in 576 patients with severe eosinophilic asthma. Individuals were included if they were on a high-dose inhaled corticosteroid along with another controller medication for at least 12 months, had at least 2 exacerbations requiring systemic corticosteroids in the past year, and had blood eosinophils of at least 150 cells/mcl at screen or 300 cells/mcl or greater during the previous year. Both doses of mepolizumab were significantly more effective compared to placebo at reducing the number of asthma exacerbations. (Ortega, 2014) The SIRIUS trial evaluated 135 individuals with severe eosinophilic asthma given mepolizumab 100 mg subcutaneously or placebo every 4 weeks through week 20. Patients enrolled had at least a 6 month history of requiring systemic corticosteroids (5-35 mg/day of prednisone equivalent) in addition to high-dose inhaled corticosteroid and an additional controller medication for the past 12 months. Two or more exacerbations requiring corticosteroids in the previous 12 months and blood eosinophils of at least 150 cells/mcl at screening or 300 cells/mcl during the previous criteria were required for inclusion. Mepolizumab significantly reduced the oral maintenance glucocorticoid dose compared to placebo. (Bel, 2014) Reslizumab (Cinqair) Reslizumab 3 mg/kg intravenous every 4 weeks was evaluated in two 52-week trials (Study 3082 and 3083). Individuals enrolled were years of age, had a blood eosinophil level of at least 400 cells/mcl during the screening period, and were receiving at least medium dose inhaled corticosteroid with or without another controller drug. Individuals were included if they had at least 1 asthma exacerbation in the previous year that required systemic corticosteroid use for at least 3 days. Reslizumab significantly decreased the frequency of asthma exacerbations compared to placebo in both trials. (Castro, 2015) Study 3081 evaluated the change from baseline in FEV 1 of reslizumab and placebo at 16 weeks. Individuals enrolled were years old, had a blood eosinophil level of at least 400 cells/mcl, had inadequately controlled asthma per the Asthma Control Questionnaire, and were receiving at least medium dose inhaled corticosteroid. Patients receiving systemic corticosteroids were excluded. The overall change in FEV 1 was significantly improved with reslizumab 3 mg/kg compared to placebo. The improvement was evident as early as 4 weeks and maintained through the study. (Bjermer, 2016) Page 4 of 7

5 Study 3084 was a 16-week trial evaluating reslizumab and placebo and change in FEV 1 from baseline. This trial did not require a specific baseline eosinophil count. Adults with inadequately controlled asthma on at least a medium dose of inhaled corticosteroid and not receiving systemic corticosteroids were included. There was not a significant difference between reslizumab and placebo in the mean change in FEV 1 from baseline to week 16. The study was not powered to assess differences in subgroups based on eosinophil levels. (Corren, 2016) Experimental, Investigational, or Unproven Uses The FDA product information notes that Cinqair and Nucala are not indicated for the relief of acute bronchospasm and status asthmaticus or for the treatment of other eosinophilic conditions. Clinical trials have investigated mepolizumab and reslizumab for other eosinophilic conditions including eosinophilic esophagitis (Assa ad, 2011; Spergel, 2012; Straumann, 2010), nasal polyposis (Gevaert, 2006; Gevaert, 2011), hypereosinophilic syndrome (Rothenberg, 2008), eosinophilic granulomatosis with polyangitis (Wechsler, 2017). At this time, however, there are insufficient published data to demonstrate the safety and efficacy of the use of mepolizumab or reslizumab for these indications. Some of the studies did not demonstrate any clinical improvement and others were limited by small and/or heterogeneous patient populations; short-term follow-ups; lack of a control group; potential reporting and publication bias; and heterogeneity of inclusion criteria and outcome measures. Coding/Billing Information Note: 1) This list of codes may not be all-inclusive. 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Covered when medically necessary: HCPCS Description Codes C9473 Injection, mepolizumab, 1 mg (Code deleted 12/31/2016) J2182 Injection, mepolizumab, 1 mg J2786 Injection, reslizumab, 1 mg References 1. Assa ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of eosinophilic intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology Nov; 141 (5): Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014; 371: Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016, doi: /j.chest Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5): Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014; 43: Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016, doi: /j.chest Page 5 of 7

6 7. Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-il-5 treatment in patients with nasal polyps. J Allergy Clin Immunol Nov; 118 (5): Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-il-5 mab, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol Nov; 128 (5): GlaxoSmithKline. Nucala (mepolizumab) for injection, for subcutaneous use [product information]. Research Triangle Park, NC: GlaxoSmithKline; November Global Initiative for Asthma (GINA) GINA Report, Global Strategy for Asthma Management and Prevention (2017 update). 2016; Accessed August 15, Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13): Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380: Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol Feb; 129 (2): Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic esophagitis: a randomised, placebo-controlled, double-blind trial. Gut Jan; 59 (1): Teva Respiratory, LLC. Cinqair (reslizumab) injection, for intravenous use [product information]. Frazer, PA: Teva Respiratory, LLD; March Wechsler ME, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangitis. N Engl J Med May 18;376(20): Page 6 of 7

7 The registered marks "Cigna" and the "Tree of Life" logo are owned by Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, Cigna Health and Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. Page 7 of 7